Straits Times Index
3,176.51 -11.15 (-0.35%) Nikkei
37,068.35 -1,011.35 (-2.66%) Hang Seng
16,224.14 -161.73 (-0.99%) FTSE 100
7,895.85 +18.80 (+0.24%) Bitcoin USD
63,765.70 +213.27 (+0.34%) CMC Crypto 200
1,386.02 +73.40 (+5.59%)
Catalent, Inc. (CTLT)
| Previous close | 55.80 |
| Open | 55.91 |
| Bid | 0.00 x 2200 |
| Ask | 0.00 x 800 |
| Day's range | 55.75 - 56.05 |
| 52-week range | 31.45 - 60.20 |
| Volume | |
| Avg. volume | 2,735,082 |
| Market cap | 10.1B |
| Beta (5Y monthly) | 1.19 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -7.18 |
| Earnings date | 17 May 2024 - 21 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 56.70 |
ZacksCharles River (CRL) Forges Collaboration With Ship of Theseus
Charles River (CRL) is set to perform plasmid production for Ship of Theseus.
ReutersNovo Nordisk parent refiles US application on Catalent deal
The parent of Wegovy producer Novo Nordisk has refiled an application to the U.S. Federal Trade Commission (FTC) for approval of a $16.5 billion deal to buy manufacturing subcontractor Catalent, a spokesperson said on Monday. Novo Nordisk Foundation said last month it had agreed to buy Catalent to boost output of the weight-loss drug Wegovy. After the deal closes, it would sell three of Catalent's fill-finish sites on to Novo Nordisk for $11 billion.
- Reuters
UPDATE 1-Novo Nordisk parent refiles US application on Catalent deal
The parent of Wegovy producer Novo Nordisk has refiled an application to the U.S. Federal Trade Commission (FTC) for approval of a $16.5 billion deal to buy manufacturing subcontractor Catalent , a spokesperson said on Monday. Novo Nordisk Foundation said last month it had agreed to buy Catalent to boost output of the weight-loss drug Wegovy. After the deal closes, it would sell three of Catalent's fill-finish sites on to Novo Nordisk for $11 billion.
